Florida / New York / No Carolina
Ph: 561.316.3330

KA Imaging Unveils New Brand Identify for its Patented Dual Energy Technology

SpectralDR™ is built into the Reveal™ 35C detector and family of products

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • “SpectralDR™ really takes general X-ray to the next level because you can get true bone and soft tissue subtracted images every time plus a DR image in one exposure at the lowest dose.
  • “The Reveal™ 35C detector is a breakthrough and the first in an exciting product roadmap,” said Fernanda Fraga, Marketing Manager of KA Imaging.
  • Having a DR plus the supplemental spectral bone and tissue images allows for better diagnosis and faster reading,” said Dr.

Canadian manufacturer KA Imaging unveiled a new brand identity for its patented dual-energy technology. SpectralDR™ is currently built into the Reveal™ 35C detector. The new brand is in line with the company’s strategy to expand its presence in the X-ray market.

“The Reveal™ 35C detector is a breakthrough and the first in an exciting product roadmap,” said Fernanda Fraga, Marketing Manager of KA Imaging. At this time, Reveal™ 35C detector is available for sale in Canada, the United States, and other countries globally. Earlier this year, the company announced plans to develop an integrated mobile system powered by its SpectralDR™ technology.

KA Imaging’s SpectralDR™ technology enables dual-energy subtraction, providing bone and tissue differentiation with a single standard X-ray exposure. It acquires three images simultaneously (DR, bone and soft tissue dual-energy X-ray images). The technology mimics the workflow, dose and techniques of state-of-the-art mobile DR X-ray detectors.

“It’s a 3-in-1 solution, as in three images with one exposure to radiation and no extra work. Having a DR plus the supplemental spectral bone and tissue images allows for better diagnosis and faster reading,” said Dr. Phil Templeton, radiologist, and Chief Medical Officer of KA Imaging. The spectral images provide enhanced visualization of different conditions like lung nodules, pneumonia, tips of lines and tubes, pneumothorax and retained surgical bodies.

Adding a name to the patented technology simplifies the message to the industry. “SpectralDR™ addresses the drawbacks of previous dual-energy subtraction or bone suppression approaches,” said Dr. Karim S. Karim, CTO of KA Imaging.  Conventional dual energy is not mobile and uses two exposures, while bone suppression image quality is limited and cannot provide bone images. “SpectralDR™ really takes general X-ray to the next level because you can get true bone and soft tissue subtracted images every time plus a DR image in one exposure at the lowest dose. If it’s low dose, 3-in-1, and mobile and single exposure, you can bet it is powered by SpectralDR™, said Karim.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Sphere Fluidics Awarded Gold Accreditation by Investors in People

Dale Levitzke, CEO of Sphere Fluidics, expressed his pride in the achievement: "Receiving the Gold Investors in People Award is a significant milestone for Sphere Fluidics. It recognizes the dedication and hard work of our entire team in creating a workplace where people feel valued, supported, and empowered to reach their full potential. This award is not just a tribute to our HR practices, but a testament to our commitment to nurturing a culture of excellence and continuous improvement."

Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership

Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, and Takara Bio USA, Inc. (“Takara Bio USA”), a wholly-owned subsidiary of Takara Bio Inc., today announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS...

CERo Therapeutics Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics is continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA

By using this website you agree to accept Medical Device News Magazine Privacy Policy